Skip to content

Hyperbaric oxygen therapy to improve cognition in patients with mild cognitive impairment

Hyperbaric oxygen therapy to improve cognition in patients with mild cognitive impairment

Status
Active, not recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20210713002
Enrollment
70
Registered
2021-07-13
Start date
2021-09-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild cognitive impairment (MCI) Hyperbaric oxygen therapy,HBOT, Mild cognitive impairment, MCI, cognition improvement

Interventions

Multiplace hyperbaric chamber at depth 2 ATA for 60 minutes per session 5 sessions per weeks for 8 consecutive weeks
Experimental Device
Hyperbaric oxygen therapy

Sponsors

Faculty of Medicine Siriraj Hospital, Mahidol University
Lead Sponsor
Somdej Prapinklao Foundation,Naval Medical Department
Collaborator

Eligibility

Sex/Gender
All
Age
60 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. MCI according to DSM-5 Criteria 2. Age >= 60 3. Able to communicate after using visual aid device or auditory aid device

Exclusion criteria

Exclusion criteria: 1. Diagnosis of Dementia 2. Psychiatric illness 3. Psychoactive or antiepileptic drug use 4. Contraindication for HBOT 5. Currently on HBOT for other indication 6. Active severe systemic disease 7. Life expectancy within 1 year 8. Expected to start Anti-Dementia drug within 6 months 9. Active smoker or alcoholic drinker

Design outcomes

Primary

MeasureTime frame
Cognitive effects 0,10 wk,22 wk MMSE,Cognitive effects 0,10,22wk MoCA,Cognitive effects 0,10,22wk WRAML2,Cognitive effects 0,10,22wk TabCAT,Cognitive effects 0,10,22wk Grooved pegboard test,Cognitive effects 0,10,22wk CDR-SB,PET scan 0,10wk PET scan

Secondary

MeasureTime frame
Non-cognitive effects 0,10,22wk BADL,Non-cognitive effects 0,10,22wk IADL,Non-cognitive effects 0,10,22wk EQ-5D-5L,Non-cognitive effects 0,10,22wk NPI-Q,Side effect 0,10,22wk Adverse event questionaire

Countries

Thailand

Contacts

Public ContactWeerasak Muangpaisan

Mahidol University

drweerasak@gmail.com024197287

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026